The company has not filed an annual or quarterly report since its Q3 FY2020 10-Q, filed Nov 9, 2020. Its latest SEC filing is a 15-12B from Mar 30, 2021.
10-Q for Q3 FY2020, filed Nov 9, 2020
The sections below describe the company as of the FY2019 annual report.
Sells extended-release ADHD tablets and liquid medicines, plus generic cough medicine, to pharmaceutical wholesalers in the United States; develops a treatment for chronic drooling linked to neurological conditions.
10-K for FY2019, filed Mar 13, 2020We currently have three branded products marketed and sold by us in the United States using our internal commercial organization. These…View ↗
Products containing amphetamine or methylphenidate are the most commonly prescribed medications in the United States for the treatment of…View ↗
Our lead clinical-stage asset, NT0502 (N-desethyloxybutynin), is an active metabolite of the active ingredient in DITROPAN® (oxybutynin…View ↗
Since 2014, we have generated revenue from product sales of our generic Tussionex recorded on a net sales basis. Sales of our generic…View ↗
Neos sells medicines to drug wholesalers, which resell them to food, drug and mass retailers. Its indirect contracts for generic Tussionex serve retailers that order and receive the product through wholesalers.
10-K for FY2019, filed Mar 13, 2020
10-Q for Q3 FY2020, filed Nov 9, 2020
−$4.9MView ↗
8-K, filed Mar 22, 2021
As described above in the Introductory Note to this Current Report on Form 8-K, on March 19, 2021, Neos completed the Merger pursuant to…View ↗
8-K, filed Dec 30, 2020
On December 29, 2020, Neos received a notice (the “Notice”) from the Listing Qualifications Department of Nasdaq stating that the Company…View ↗
ADHD products reach the market
The older report presented Adzenys XR-ODT as marketed and Cotempla and an amphetamine suspension as candidates; the latest report describes the ADHD tablets and suspension as marketed products.
10-K for FY2016, filed Mar 15, 2017 10-K for FY2019, filed Mar 13, 2020We are a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing our proprietary…View ↗
We currently have three branded products marketed and sold by us in the United States using our internal commercial organization. These…View ↗
Development expands beyond ADHD
The older report described its development work around ADHD products; the latest report also includes a candidate for chronic drooling associated with neurological conditions.
10-K for FY2016, filed Mar 15, 2017 10-K for FY2019, filed Mar 13, 2020We are a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing our proprietary…View ↗
Our lead clinical-stage asset, NT0502 (N-desethyloxybutynin), is an active metabolite of the active ingredient in DITROPAN® (oxybutynin…View ↗
Competes with Takeda Pharmaceutical, Tris Pharma, Janssen Pharmaceuticals, Rhodes Pharmaceuticals, Ironshore Pharmaceuticals, Osomotica Pharmaceuticals, Novartis, Adlon Therapeutics, Supernus, Sunovion, KemPharm, NLS Pharma, and Neurovance
10-K for FY2019, filed Mar 13, 2020· amphetamine XR is currently marketed in the United States by (i) Takeda Pharmaceutical Company Limited under the brand names Adderall…View ↗
Loading...
